233 related articles for article (PubMed ID: 30220530)
21. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract][Full Text] [Related]
22. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
23. Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
Mannella V; Boehm K; Celik S; Ali T; Mirza AN; El Hasnaouy M; Kaffa A; Lyu Y; Kafaei Golahmadi D; Leigh IM; Bergamaschi D; Harwood CA; Maffucci T
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808215
[TBL] [Abstract][Full Text] [Related]
24. Monocytes promote UV-induced epidermal carcinogenesis.
Lelios I; Stifter SA; Cecconi V; Petrova E; Lutz M; Cansever D; Utz SG; Becher B; van den Broek M; Greter M
Eur J Immunol; 2021 Jul; 51(7):1799-1808. PubMed ID: 33759186
[TBL] [Abstract][Full Text] [Related]
25. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
26. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention.
Bridgeman BB; Wang P; Ye B; Pelling JC; Volpert OV; Tong X
Cell Signal; 2016 May; 28(5):460-468. PubMed ID: 26876613
[TBL] [Abstract][Full Text] [Related]
28. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A.
Wulff BC; Kusewitt DF; VanBuskirk AM; Thomas-Ahner JM; Duncan FJ; Oberyszyn TM
J Invest Dermatol; 2008 Oct; 128(10):2467-73. PubMed ID: 18463679
[TBL] [Abstract][Full Text] [Related]
29. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells.
Ori Y; Herman-Edelstein M; Zingerman B; Rozen-Zvi B; Gafter U; Malachi T; Gafter-Gvili A
Biomed Pharmacother; 2012 Sep; 66(6):409-13. PubMed ID: 22795807
[TBL] [Abstract][Full Text] [Related]
30. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
31. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.
Nissinen L; Farshchian M; Riihilä P; Kähäri VM
Cell Tissue Res; 2016 Sep; 365(3):691-702. PubMed ID: 27411692
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
[TBL] [Abstract][Full Text] [Related]
33. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Rival-Tringali AL; Euvrard S; Decullier E; Claudy A; Faure M; Kanitakis J
Anticancer Res; 2009 Jun; 29(6):1927-32. PubMed ID: 19528449
[TBL] [Abstract][Full Text] [Related]
34. [ASSOCIATION OF SKIN PHOTOTYPE AND UV EXPOSURE WITH EXPRESSION OF HER RECEPTORS, Ki67 AND p53 IN PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA].
Drvar DL; Lipozenčić J; Mokos ZB; Ilić I; Knežević F
Acta Med Croatica; 2015; 69(5):431-8. PubMed ID: 29087088
[TBL] [Abstract][Full Text] [Related]
35. Organ transplantation and skin cancer: basic problems and new perspectives.
Hofbauer GF; Bouwes Bavinck JN; Euvrard S
Exp Dermatol; 2010 Jun; 19(6):473-82. PubMed ID: 20482618
[TBL] [Abstract][Full Text] [Related]
36. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.
Feldmeyer L; Hofbauer GF; Böni T; French LE; Hafner J
Br J Dermatol; 2012 Feb; 166(2):422-4. PubMed ID: 21895616
[TBL] [Abstract][Full Text] [Related]
37. Sirolimus: a potential chemopreventive agent.
Fernandez A; Hu S; Kirsner RS
J Invest Dermatol; 2008 Oct; 128(10):2352. PubMed ID: 18787541
[No Abstract] [Full Text] [Related]
38. Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes.
Mizrahi A; Barzilai A; Gur-Wahnon D; Ben-Dov IZ; Glassberg S; Meningher T; Elharar E; Masalha M; Jacob-Hirsch J; Tabibian-Keissar H; Barshack I; Roszik J; Leibowitz-Amit R; Sidi Y; Avni D
Oncogene; 2018 Jan; 37(2):218-230. PubMed ID: 28925390
[TBL] [Abstract][Full Text] [Related]
39. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
40. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
